Treatment of cancer- and chemotherapy-associated anemia with ferric carboxymaltose in clinical practice. 1. Juni 2011 Steinmetz, T., Tschechne, B., Harlin, O., Klement, B., Franzem, M., Wamhoff, J., Tech, H., Rohrberg, R., Marschner, N., 2011. Onkologie 34 (suppl 6)(V1012), 304. doi:10.1159/000333303 Abstract REASON: A Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV in Germany. Schuette, W., Eberhardt, W., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Gutendorf, B., Thomas, M., 2011. Amsterdam; 2011. Weiterlesen Ferric Carboxymaltose for the Correction of Cancer- and Chemotherapy-Assiciated Anemia in Clinical Practice. Steinmetz, T., Tschechne, B., Virgin, G., Klement, B., Franzem, M., Wamhoff, J., Tesch, H., Rohrberg, R., Marschner, N., 2011. haematologica 96(s2), 0983. Weiterlesen